RESUMO O objetivo deste estudo foi avaliar e comparar com ultrassonografia de reabilitação (IUR) o tecido conjuntivo perimuscular da parede abdominal (PMPA) e interrecti distância (IRD) entre elite e jogadores de basquete amadores. Uma amostra de 22 jogadores de basquete saudáveis foi incluída e dividida em dois grupos: jogadores de basquete de elite da 1ᵃ divisão espanhola (n=11) e jogadores de basquete amadores de uma divisão de entretenimento espanhol (n=11). As imagens de ultrassom do oblíquo externo (OE), oblíquo interno (OI), transverso abdominal (TrAb), recto anterior (RA) e IRD PMPA foram medidas e analisadas pelo software ImageJ. Medições dos músculos da parede abdominal O PMPA apresentam diferenças estatisticamente (P<0,05) para o aumento do tecido conjuntivo perimuscular de oblíquo externo (PMOE), tecido conjuntivo perimuscular de transverso abdominal (PMTA) do lado esquerdo e aumento do PMOE do lado direito a favor do grupo de elite. Em vez disso, o estudo mostrou diferenças estatisticamente (P<0,05) para uma diminuição do tecido conjuntivo perimuscular entre o oblíquo interno e transverso abdominário (PMOI-TA) e uma diminuição no somatório total de PMTA do lado esquerdo do grupo de elite em relação ao amador grupo. Este estudo relatou um aumento do PMTOE esquerdo, PMTA esquerdo, PMCTOE direito, bem como uma diminuição do PMCTOI-TA esquerdo e no somatório total do PMTA no lado esquerdo.

SUMMARY The purpose of this study was to assess and compare with rehabilitative ultrasound imaging (RUSI) the perimuscular connective tissue (PMCT) and interrecti distance (IRD) between elite and amateur basketball players. A sample of 22 healthy basketball players was included and divided into two groups: elite basketball players from Spanish 1st division (n = 11) and amateur basketball players from an entertainment Spanish division (n = 11). Ultrasound images of the external oblique (EO), internal oblique (IO), transversus abdominis (TrAb), rectus anterior (RA) and IRD PMCT were measured and analysed by the ImageJ software. Measurements of abdominal wall muscles PMCT present statistically differences (P < .05) for an increase of perimuscular connective tissue of external oblique (PMCTEO), perimuscular connective tissue of transversus abdominis (PMCTTA) of the left side and an increase of PMCTEO on the right side in favor of the elite group. Rather, the study showed statistically differences (P < .05) for a decrease of perimuscular connective tissue between the internal oblique and transversus abdominis (PMCTIO-TA), and a decrease in PMCT total summation of the left side with elite group in respect to amateur group. This study reported an increase of left PMCTEO, left PMCTTAA, right PMCTEO as well as a decrease of left PMCTIO-TA and in PMCT total summation on the left side.

ABSTRACT Background: The objective was to evaluate the efficiency (relation between the cost and the results in health) of the treatments in psoriasis, seeking a higher quality of economic evaluations, consistency and transparency in these studies. Methods: We developed a model of economic evaluation in psoriasis collecting all the many direct and indirect costs of each treatment. The effectiveness indicator used was Psoriasis Area Severity Index [PASI 75] which is generally acceptable in studies of psoriasis. The effectiveness indicator was a PASI 75. Subsequently we calculated the Incremental Cost-Effectiveness Ratio (ICER) for the period of 12 weeks and PASI 75, ordering treatments by level of effectiveness at the expense of treatment costs. Results: The most cost effective treatment was methotrexate (ICER -7.5) followed by acitretin (ICER 29.5). The least cost has proved effective PUVA (ICER 4,651), followed by UVB narrow band (2,886.1). Conclusions: When taking into account both direct and indirect costs together with efficiency, methotrexate is the most cost effective treatment.

RESUMEN Fundamentos: Los nuevos tratamientos biológicos, si bien mejoran la calidad de vida del paciente, incrementan los costes exponencialmente en relación al resto de tratamientos. El objetivo fue calcular el tratamiento más coste efectivo de los existentes para la psoriasis. Métodos: Se desarrolló un modelo de evaluación económica en psoriasis recogiendo todos los costes directos e indirectos de cada tratamiento. El indicador de efectividad que se utilizó fue Psoriasis Area Severity Index (PASI 75), que es el aceptable de manera general en estudios de psoriasis. Posteriormente se realizó un análisis de incremento coste efectividad (ICER) para el periodo de 12 semanas y PASI 75, ordenando los tratamientos por nivel de efectividad en detrimento de los costes de los tratamientos. Resultados: El tratamiento más coste efectivo fue el metotrexato (ICER -7,5) seguido de acitretina (ICER 29,5). El menos coste efectivo resultó ser PUVA (ICER 4.651) seguido de UVB de banda estrecha (2.886,1). Conclusiones: Aunque el tratamiento más económico teniendo en cuenta solo los costes directos sería el UVBbe, al incluir los costes indirectos y ajustarlos por la efectividad el tratamiento más coste efectivo es el metotexato.

ABSTRACT Background: The objective was to evaluate the efficiency (relation between the cost and the results in health) of the treatments in psoriasis, seeking a higher quality of economic evaluations, consistency and transparency in these studies. Methods: We developed a model of economic evaluation in psoriasis collecting all the many direct and indirect costs of each treatment. The effectiveness indicator used was Psoriasis Area Severity Index [PASI 75] which is generally acceptable in studies of psoriasis. The effectiveness indicator was a PASI 75. Subsequently we calculated the Incremental Cost-Effectiveness Ratio (ICER) for the period of 12 weeks and PASI 75, ordering treatments by level of effectiveness at the expense of treatment costs. Results: The most cost effective treatment was methotrexate (ICER -7.5) followed by acitretin (ICER 29.5). The least cost has proved effective PUVA (ICER 4,651), followed by UVB narrow band (2,886.1). Conclusions: When taking into account both direct and indirect costs together with efficiency, methotrexate is the most cost effective treatment.

RESUMEN Fundamentos: Los nuevos tratamientos biológicos, si bien mejoran la calidad de vida del paciente, incrementan los costes exponencialmente en relación al resto de tratamientos. El objetivo fue calcular el tratamiento más coste efectivo de los existentes para la psoriasis. Métodos: Se desarrolló un modelo de evaluación económica en psoriasis recogiendo todos los costes directos e indirectos de cada tratamiento. El indicador de efectividad que se utilizó fue Psoriasis Area Severity Index (PASI 75), que es el aceptable de manera general en estudios de psoriasis. Posteriormente se realizó un análisis de incremento coste efectividad (ICER) para el periodo de 12 semanas y PASI 75, ordenando los tratamientos por nivel de efectividad en detrimento de los costes de los tratamientos. Resultados: El tratamiento más coste efectivo fue el metotrexato (ICER -7,5) seguido de acitretina (ICER 29,5). El menos coste efectivo resultó ser PUVA (ICER 4.651) seguido de UVB de banda estrecha (2.886,1). Conclusiones: Aunque el tratamiento más económico teniendo en cuenta solo los costes directos sería el UVBbe, al incluir los costes indirectos y ajustarlos por la efectividad el tratamiento más coste efectivo es el metotexato.